ASCO: Osimertinib Improves Progression-Free Survival in EGFR-Mutated Lung Cancer
Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC
Race-Neutral Metrics More Accurately Predict Risk in COPD
GLI-Global differentiated all-cause mortality risk between normal spirometry and first grade of COPD in adjusted analyses
CDC Reports Third Dairy Worker Infected With Bird Flu, Risk to Public Remains ‘Low’
2007 to 2019 Saw Increase in Inflation-Adjusted Health Care Spending
From 2007 to 2019, medical burden increased from 23.5 to 26.4 percent for low-income families and from 5.4 to 6.5 percent for higher-income families
Pulmonologist Intervention Beneficial for Undiagnosed Asthma, COPD
Those receiving pulmonologist-directed treatment have less subsequent health care utilization for respiratory illness
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
Similarly accurate prediction seen for respiratory outcomes, but occupational eligibility and disability compensation differed
Dupilumab Tied to Fewer Exacerbations in COPD With Type 2 Inflammation
Increase seen in prebronchodilator forced expiratory volume in one second with dupilumab versus placebo at weeks 12, 52
Long COVID Definitions, Care Models Are Evolving
Care models are informed by five key principles, including multidisciplinary expertise, patient-centered approach
Bisoprolol Does Not Reduce Exacerbations in At-Risk COPD Patients
No reduction seen in number of self-reported exacerbations treated with oral corticosteroids, antibiotics, or both
Aficamten Beneficial for Obstructive Hypertrophic Cardiomyopathy
Significantly greater improvement seen in peak oxygen uptake with aficamten versus placebo for symptomatic HCM
